Trial Profile
An International, Prospective, Open-label, Multicenter, Pharmacoepidemiological Study to Determine Predictors of Clinical Outcomes in Haemodialysis Patients With Anaemia Treated With Biosimilar Epoetin Alfa
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 30 Nov 2017
Price :
$35
*
At a glance
- Drugs Epoetin alfa (Primary)
- Indications Anaemia
- Focus Pharmacodynamics
- Acronyms MONITOR-CKD5
- Sponsors Sandoz
- 30 Nov 2017 New trial record
- 23 Nov 2017 Results published in the Clinical Nephrology